Certara (NASDAQ:CERT) Stock Price Down 2% - Should You Sell?

Certara, Inc. (NASDAQ:CERT - Get Free Report)'s stock price dropped 2% on Tuesday . The stock traded as low as $14.14 and last traded at $14.18. Approximately 375,986 shares changed hands during trading, a decline of 68% from the average daily volume of 1,189,954 shares. The stock had previously closed at $14.47.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. KeyCorp raised their target price on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, April 16th. William Blair reaffirmed a "market perform" rating on shares of Certara in a report on Thursday, February 27th. Stephens reiterated an "overweight" rating and set a $17.00 price target on shares of Certara in a report on Thursday, February 27th. TD Cowen initiated coverage on Certara in a research note on Thursday, February 27th. They issued a "buy" rating and a $16.00 price objective on the stock. Finally, Barclays decreased their target price on Certara from $13.00 to $11.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $15.17.

Certara Stock Performance

The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The company has a fifty day moving average of $11.65 and a two-hundred day moving average of $11.57. The firm has a market capitalization of $2.29 billion, a price-to-earnings ratio of -70.85, a PEG ratio of 9.29 and a beta of 1.64.

Institutional Investors Weigh In On Certara

Institutional investors have recently modified their holdings of the business. Versant Capital Management Inc raised its stake in Certara by 218.8% in the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock worth $27,000 after purchasing an additional 1,866 shares in the last quarter. Venturi Wealth Management LLC raised its position in shares of Certara by 839.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock valued at $30,000 after buying an additional 2,509 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Certara by 48.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after buying an additional 1,047 shares during the period. Johnson Financial Group Inc. acquired a new stake in Certara during the fourth quarter worth approximately $47,000. Finally, Blue Trust Inc. increased its stake in Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after acquiring an additional 822 shares during the period. Institutional investors own 73.96% of the company's stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.